论文部分内容阅读
绿脓杆菌MSHA菌毛株菌苗是一种新型的微生物免疫调节剂，首次应用于恶性淋巴瘤化疗的辅助治疗。结果显示：在化疗同时进行菌苗治疗组其治疗有效率（95．56％）明显高于仅进行化疗的对照组（69．77％），而感染率（17．78％）则明显低于对照组（37．21％），P值均小于0．05。菌苗治疗组IL－2水平，NK细胞活性及CD4+／CD8+比值也明显高于对照组，且其抵抗多种不同菌属的革兰氏阴性杆菌抗体水平亦显著高于对照组，提示该菌苗是通过调整或增强患者自身细胞免疫或体液免疫水平，达到抗肿瘤．抗感染的功效。作者认为该菌苗是恶性淋巴瘤患者化疗的良好辅助药物。
Pseudomonas aeruginosa MSHA bacillus strain bacterin is a new type of microbial immunomodulator, and it is the first time used in the adjuvant treatment of malignant lymphoma chemotherapy. The results showed that the efficiency of treatment (95.56%) in the bacterin-treated group was significantly higher than that in the control group (69.77%), while the infection rate (17.78%) was significantly lower. In the control group (37.21%), the P value was less than 0.05. The level of IL-2, NK cell activity and CD4+/CD8+ ratio in the bacterin-treated group were also significantly higher than those in the control group, and the levels of gram-negative bacillus antibodies against a variety of different genus species were also significantly higher than those in the control group, suggesting that the bacteria The seedlings are anti-tumor by adjusting or enhancing the patient’s own cellular immunity or humoral immunity. Anti-infective effect. The authors believe that the vaccine is a good adjuvant drug for chemotherapy for malignant lymphoma patients.